Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

Abstract : Background & Aims Asunaprevir is a selective HCV NS3 protease inhibitor, active against genotypes 1, 4, 5, and 6 in vitro. We evaluated asunaprevir plus peginterferon alfa-2a/ribavirin (PegIFNα/RBV) for genotype 1 and 4 chronic HCV. Methods In this phase 2b, double-blind, placebo-controlled study, treatment-naive adults with genotype 1 (n = 213) or 4 (n = 25) were randomly assigned (3:1) to asunaprevir 200 mg or placebo twice daily plus PegIFNα/RBV. Asunaprevir recipients, achieving protocol-defined response (HCV-RNA below quantification limit at week 4 and undetectable at week 10), were rerandomized at week 12 to continue asunaprevir-based triple therapy or receive placebo plus PegIFNα/RBV for weeks 13–24. Patients without protocol-defined response (PDR) and placebo recipients continued PegIFNα/RBV through week 48. Co-primary end points were undetectable HCV-RNA at week 4 and 12 (eRVR) and 24 weeks posttreatment (SVR24). Results Most patients were male (64.3%), white (83.6%), and had non-CC IL28B genotypes (71.3%). Among genotype 1 patients, eRVR rates (asunaprevir vs. placebo) were 67% (80% CI 62, 72) vs. 6% (80% CI 2, 10); corresponding SVR24 rates were 64% (80% CI 59, 68) vs. 44% (80% CI 36, 53). SVR24 among genotype 4 patients was 89% (asunaprevir) vs. 43% (placebo). Rates of rash and haematologic adverse events were similar between treatment groups. Five asunaprevir-treated patients had grade 4 alanine aminotransferase elevations that resolved following discontinuation (n = 4) or with continued dosing (n = 1). Conclusions Addition of asunaprevir to PegIFNα/RBV in treatment-naive genotype 1- or 4-infected patients improves response rates and is well tolerated, with aminotransferase elevations that were manageable with appropriate monitoring.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-01699241
Contributor : NGERE UL Connect in order to contact the contributor
Submitted on : Friday, February 2, 2018 - 10:45:43 AM
Last modification on : Saturday, May 21, 2022 - 3:42:37 AM

Identifiers

Citation

Jean-Pierre Bronowicki, Vlad Ratziu, Adrian Gadano, Paul Thuluvath, Fernando Bessone, et al.. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology, Elsevier, 2014, 61 (6), pp.1220 - 1227. ⟨10.1016/j.jhep.2014.07.011⟩. ⟨hal-01699241⟩

Share

Metrics

Record views

67